摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

thymidine 3’-dodecylphosphate sodium salt | 830322-63-9

中文名称
——
中文别名
——
英文名称
thymidine 3’-dodecylphosphate sodium salt
英文别名
2'-deoxthymidine-3'-(1-dodecyl)sodium phosphate;sodium;1-[(2R,4S,5R)-4-[dodecoxy(hydroxy)phosphoryl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-2-oxopyrimidin-4-olate
thymidine 3’-dodecylphosphate sodium salt化学式
CAS
830322-63-9
化学式
C22H38N2O8P*Na
mdl
——
分子量
512.516
InChiKey
ZONRSJHAMUDOCT-WUHLWKCASA-M
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.33
  • 重原子数:
    34
  • 可旋转键数:
    16
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.82
  • 拓扑面积:
    141
  • 氢给体数:
    2
  • 氢受体数:
    8

反应信息

  • 作为产物:
    描述:
    thymidine 3'-[(2-cyanoethyl)dodecyl]phosphate 作用下, 以 甲醇 为溶剂, 反应 2.0h, 以93%的产率得到thymidine 3’-dodecylphosphate sodium salt
    参考文献:
    名称:
    Thymidine-based amphiphiles and their bonding to DNA
    摘要:
    为开发用于基因传递的非阳离子载体,构建了一类新颖的胸苷基两亲分子。这些分子展现了良好的生物相容性。通过凝胶电泳、毛细管电泳、透射电子显微镜(TEM)和分子动力学模拟,证明了它们通过氢键和π–π堆积作用与聚腺苷酸的复合。还发现它们的生物相容性和与DNA的结合能力随烷基链长度的增加呈反向变化。
    DOI:
    10.1039/c3nj41062e
点击查看最新优质反应信息

文献信息

  • Functional synthetic molecules and macromolecules for gene delivery
    申请人:Grinstaff W. Mark
    公开号:US20060241071A1
    公开(公告)日:2006-10-26
    The present invention describes a synthetic non-viral vector composition for gene therapy and the use of such compositions for in vitro, ex vivo and/or in vivo transfer of genetic material. The invention proposes a pharmaceutical composition containing 1) a non-cationic amphiphilic molecule or macromolecule and its use for delivery of nucleic acids or 2) a cationic amphiphilic molecule or macromolecule that transforms from a cationic entity to an anionic, neutral, or zwitterionic entity by a chemical, photochemical, or biological reaction and its use for delivery of nucleic acids. Moreover this invention describes the use of these non-viral vector compositions in conjunction with a surface to mediate the delivery of nucleic acids. An additional embodiment is the formation of a hydrogel with these compositions and the use of this hydrogel for the delivery of genetic material. A further embodiment of this invention is the use of a change in ionic strength for the delivery of genetic material.
    本发明描述了一种用于基因治疗的合成非病毒载体组合,以及这种组合在体外、体内和/或体外转移遗传物质中的应用。该发明提出了一种包含1)非阳离子性两性分子或大分子的药物组合物及其用于传递核酸或2)由化学、光化学生物反应从阳离子实体转变为阴离子、中性或带电离子实体的两性阳离子分子或大分子的药物组合物,以及其用于核酸传递。此外,本发明描述了这些非病毒载体组合物与表面结合以介导核酸传递的应用。另一实施例是使用这些组合物形成凝胶,并利用该凝胶传递遗传物质。本发明的另一实施例是利用离子强度变化传递遗传物质。
查看更多

同类化合物

腺苷-3’-磷酸 胸苷酰-(3'-5')-胸苷氰基乙基磷酰三酯 胸腺嘧啶脱氧核苷3-单磷酸铵盐水合物 胞啶-3'-单磷酸二钠盐 环(腺苷酰(3'-5')尿苷单磷酸酯) 尿苷酸 尿苷溴乙酰甲醇5'-二磷酸酯 尿苷氯乙酰甲醇5'-二磷酸酯 丁二酸,甲基-,1-(苯基甲基)酯,(2R)-(9CI) [(2R,3S,4R,5R)-5-(6-氨基嘌呤-9-基)-4-羟基-2-(羟基甲基)四氢呋喃-3-基]苯基磷酸氢酯 [(2R,3S,4R,5R)-5-(2-氨基-6-氧代-3H-嘌呤-9-基)-2-[(2-甲酰基苯氧基)甲基]-4-羟基四氢呋喃-3-基]磷酸二氢酯 N-苯甲酰基-2'-脱氧-3'-胞苷酸2-氯苯基2-氰基乙基酯 8-[(E)-苄亚基氨基]-2'-脱氧腺苷3'-(磷酸二氢酯) 5-甲基-2'-脱氧胞苷-3'-磷酸 3'-(二氢磷酸)鸟嘌呤核苷 3'-(1-丁基磷酰)腺苷 2ˊ-脱氧胞苷-3ˊ-一磷酸 2-脱氧腺苷-3-单磷酸酯*铵 2'-脱氧鸟苷 3'-(磷酸二氢酯) 2'-脱氧腺苷酰-(3'-5')-2'-脱氧腺苷酰-(3'-5)-2'-脱氧腺苷 2'-脱氧-3'-胞苷酸二钠盐 2' -脱氧3' -磷酸游离酸 [3']thymidylic acid mono-[4-(2-iodo-acetylamino)-phenyl] ester 5-Fluor-1-β-D-arabinofuranosylcytosin-3'-phosphat [3']thymidylic acid mono-[4-(2-bromo-acetylamino)-phenyl] ester O2'-Methylguanosin-3'-phosphorsaeure uridine-3'-(2-cyanoethyl)phosphate [3']thymidylic acid mono-[4-(2-chloro-acetylamino)-phenyl] ester (1R)-1-(6-amino-purin-9-yl)-O3-phosphono-1,5-anhydro-D-glucitol Thymidin-3'-(2,4-dinitrophenyl)phosphat N4-Dimethylamino-methylen-2',5'-bis-O-(1-ethoxy-ethyl)-cytidin-3'-phosphat (2R)-3-((hydroxy(((2R,3S,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl)oxy)phosphoryl)oxy)propane-1,2-diyl dioleate 3-Methyl-uridin-3'-phosphat 2'-O-(tert-butyldimethylsilyl)inosine 3'-(allyl 2-cyanoethylphosphate) 2'-O-(2-tetrahydrofuranyl)-N4-(4-anisoyl)cytidine-3'-(2-chlorophenoxy)phosphoryl-2'-O-(2-tetrahydrofuranyl)-N4-(4-anisoyl)cytidine-3'-(2-chlorophenoxy)phosphoryl-2'-O-(2-tetrahydrofuranyl)-N4-(4-anisoyl)cytidine-3'-(2-chlorophenoxy)phosphoryl-2'-O-(2-tetrahydrofuranyl)-N4-(4-anisoyl)cytidine-3'-[O-(2-cyanoethyl)(2-chlorophenyl)phosphate] Phosphoric acid mono-[(2S,5R)-5-(2,4-diamino-pyrrolo[2,3-d]pyrimidin-7-yl)-2,5-dihydro-furan-2-ylmethyl] ester; compound with triethyl-amine 9-β.D-Glucopyranosyl-adenin-4'-phosphat 4-Oxo-pentanoic acid (2R,3S,5R)-3-[(2-chloro-phenoxy)-hydroxy-phosphoryloxy]-5-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-tetrahydro-furan-2-ylmethyl ester N(4),O(2')-Dibenzoyl-cytidin-3'-phosphat cis-((5-((4-amino-2-oxopyrimidin-1(2H)-yl)methyl)-1,3-oxathiolan-2-yl)methyl) (2R,3S,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl hydrogen phosphate 1,20-(icosanedioxy)bis-(3'-phosphatidyl-2'-deoxythymidine) 4-N-benzoyl-5'-O-[di(2-cyanoethyloxy)phosphoryl]-2'-deoxycytidylyl-{3'-OP-(2-cyanoethyl)->5'}-6-N-benzoyl-2',3'-di-O-(tert-butyldimethylsilyl)adenosine [3']uridylic acid mono-[1-(5,6-bis-ethoxycarbonylamino-pyrimidin-4-ylamino)-β-D-1-deoxy-ribofuranos-5-yl] ester 1-β-D-Arabinofuranosylcytidin-3'-phosphat OH[AA]AZMB